目的 为寻找治疗盆腔炎性疾病（PID）的有效治疗方案,对比分析头孢哌酮舒巴坦钠+吗啉硝唑、康妇炎胶囊联合头孢哌酮舒巴坦钠及吗啉硝唑两种用药方案治疗PID的效果差异,期望为今后临床中合理选择PID药物治疗方案提供参考依据。方法 选取2019年1月—12月期间在我院接受治疗的104例急性PID患者（湿毒壅盛证）作为研究对象,用随机信封分为参照组、研究组,各52例。予以参照组患者头孢哌酮舒巴坦钠+吗啉硝唑静脉滴注治疗,研究组患者在参照组基础上口服康妇炎胶囊,均持续治疗14 d。观察2组患者近期疗效、炎性因子、盆腔炎性疾病包块、远期复发率（6个月、1年）、远期生活质量,综合评价两种用药方案应用效果。结果 治疗14 d后,研究组总有效率96.00%,高于参照组的80.39%,差异显著（P<0.05）;WBC、CRP、IL-2、TNF-α四项炎性因子水平均低于参照组,差异显著（P<0.05）;腔包块直径、疼痛评分均低于参照组,差异显著（P<0.05）。随访6个月、1年,研究组患者PID复发率分别为4.00%、10.00%,均低于参照组的15.69%、29.41%,差异显著（P<0.05）。结论 以康妇炎胶囊联合头孢哌酮舒巴坦钠及吗啉硝唑治疗PID,能够提升患者的近期治疗效果,改善炎性反应、盆腔炎性疾病包块,降低远期复发风险,改善远期生活质量,而且能够保证用药安全性,具有推广使用价值。

Objective To find an effective treatment for pelvic inflammatory disease（PID）,and to compare and analyze the difference of efficacy of cefoperazone and sulbactam sodium + molinidazole,Kangfuyan capsule combined with cefoperazone and sulbactam sodium + molinidazole in the treatment of PID,in order to provide reference for rational selection of PID drug treatment in future clinical practice．Methods A total of 104 patients with acute PID（excessive wet toxin accumulation syndrome）who received treatment in our hospital from January to December 2019 were selected as the research objects．They were randomly divided into the control group and the research group with 52 cases in each group．Patients in the control group were given intravenous infusion of cefoperazone and sulbactam sodium + morinidazole,and patients in the research group were given Kangfuyan capsule orally on the basis of the control group,all treated for 14 days．The short-term efficacy,inflammatory factors,pelvic inflammatory mass and pain improvement,adverse reactions,long-term recurrence rate（6 months,1 year）,long-term quality of life in two groups were observed,and the application effect of the two drug regimens was comprehensively evaluated．Results After 14 days of treatment,the total effective rate of the research group was 96.00%,which was higher than that of the control group（80.39%）,with significant difference（P<0.05）．After treatment,the levels of WBC,CRP,IL-2 and TNF-α were lower than those of the control group,and the differences were significant（P<0.05）．After treatment,lumen mass diameter and pain score were lower than the control group,the differences were significant（P<0.05）．After 6 months and 1 year follow-up,the PID recurrence rate of the research group was 4.00% and 10.00% respectively,both lower than that of the control group（15.69% and 29.41%）,with significant difference（P<0.05）．Conclusions Using Kangfuyan capsule combined with cefoperazone and sulbactam sodium + molinidazole in the treatment of PID,can improve the patient's recent treatment effect,improve the inflammatory reaction,pelvic inflammation mass, lower long-term risk of recurrence,improve the long-term quality of life,and can ensure medication safety,with promotion value.

目的 探讨宫颈病变诊断中HPV联合TCT(薄层液基细胞学)检测的预测价值。方法 本文将2019年2月—2020年2月收治的宫颈病变患者90例作为研究对象,对所有患者实施HPV检测、TCT检测及阴道镜活检,将阴道镜检查结果作为金标准,统计分析TCT检测与病理结果比较、HPV检测与病理结果比较、联合检测与病理结果比较及诊断准确率。结果 90例患者经病理检查显示宫颈正常27例、CINⅠ期27例、CINⅡ期11例、CINⅢ期14例、宫颈癌11例;TCT检测显示宫颈正常19例、ASCUS 33例、LSIL 22例、HSIL 12例、SCC 4例。经HPV检测显示阳性73例,阴性17例;联合检测显示阳性88例,阴性2例;联合检测准确率与病理结果之间差异无统计学意义,P＞0.05。结论 HPV检测联合TCT检测在宫颈病变中具有较高的预测价值,准确度较高且具有无创性,可有效降低阴道镜活检的概率或者手术探查的概率,患者医疗负担相对较轻,可将其应用于宫颈病变的大规模筛查中。

Objective To investigate the predictive value of HPV combined with TCT (thinprep cytology test) in the diagnosis of cervical lesions. Methods 90 patients with cervical lesions from February 2019 to February 2020 were selected as the research objects. HPV detection, TCT detection and colposcopy biopsy were carried out for all patients. The colposcopy results were taken as the gold standard. The comparison of TCT detection and pathological results, HPV detection and pathological results, joint detection and pathological results comparison and diagnostic accuracy were statistically analyzed. Results Pathological examination showed that 27 cases of normal cervix, 27 cases of CIN Ⅰ, 11 cases of CIN Ⅱ, 14 cases of CIN Ⅲ and 11 cases of cervical cancer; TCT showed 19 cases of normal cervix, 33 cases of ASCUS, 22 cases of LSIL, 12 cases of HSIL and 4 cases of SCC. HPV test showed that 73 cases were positive and 17 cases were negative; 88 cases were positive and 2 cases were negative by combined detection; there was no significant difference between the accuracy of combined detection and pathological results, P>0.05. Conclusion HPV detection combined with TCT detection in cervical lesions has high predictive value, high accuracy and non-invasive. It can effectively reduce the probability of colposcopy biopsy or surgical exploration. It makes patients with relatively light medical burden, may be applied to large-scale screening of cervical lesions.